← Back to Search

Bispecific Antibody for Colorectal Cancer

Phase 1
Waitlist Available
Led By Aiwu R. He, MD
Research Sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed colorectal cancer
Karnofsky performance status 70-100%
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing how well a bispecific antibody works in finding colorectal cancer cells.

Who is the study for?
This trial is for adults with confirmed colorectal cancer who are in relatively good health, meaning their kidneys and liver work well, they have a decent number of blood cells, and can do most daily activities on their own. They should not be pregnant or breastfeeding and must use birth control if able to have children. People in prison or mental health facilities cannot join.Check my eligibility
What is being tested?
The study is testing a new diagnostic method using a bispecific antibody that might better detect colorectal cancer cells and determine how far the disease has spread. This phase I trial aims to see how effective this approach is.See study design
What are the potential side effects?
Since this trial focuses on diagnosis rather than treatment, specific side effects aren't detailed here. However, potential risks may include allergic reactions to the antibody or discomfort from imaging procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My colorectal cancer diagnosis was confirmed through a tissue examination.
Select...
I am mostly able to care for myself and carry out daily activities.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacokinetics
Tissue distribution

Find a Location

Who is running the clinical trial?

Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyLead Sponsor
9 Previous Clinical Trials
114 Total Patients Enrolled
Aiwu R. He, MDPrincipal InvestigatorLombardi Comprehensive Cancer Center

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00895323 — Phase 1
Colorectal Cancer Research Study Groups:
Colorectal Cancer Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00895323 — Phase 1
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00895323 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical experiment actively enrolling participants?

"The details on clinicaltrials.gov indicate that this medication trial is no longer recruiting patients. After being first posted in November of 2008, the last update to the study was made in September 2013; however, there are still 1,064 other research efforts actively seeking participants currently."

Answered by AI

How efficacious is this form of treatment for patients?

"Our team at Power assessed the safety of this therapy as a 1, given that it is currently in Phase 1 trials. This indicates there are limited clinical data points to support its effectiveness and security."

Answered by AI
~1 spots leftby Mar 2025